Table 1.
Human killer monocytes and MoDCsc
| Cell type | Stimulation | Target | E:T ratio | Killing mechanism | Refs |
|---|---|---|---|---|---|
| Monocytes | |||||
| Monocytes | HIV-1 | T cells | 1:1 | Contact dependent | [38] |
| Monocytes | IFNα, IFNγ | OVCAR3 (ovarian cancer) WM793 (melanoma) MDA231 (breast cancer) Colo205 (colon cancer) PC-3 (prostate cancer) H2126 (lung cancer) |
50:1 | TRAIL | [12] |
| Monocytes | IFNγ | HSC3 (oral squamous cell carcinoma) | 50:1 | TWEAK TRAIL |
[15] |
| Monocytes | LPS | K562 (leukemia) | 10:1 | No involvement of Fas-L, TNF-α or TGF-β | [14] |
| Monocytes | IFNα | K562 PC-3 Jurkat (T cell leukemia) |
? | TRAILa | [13] |
| CD16+ slan DCs | Unstimulated | Colo205 SkBr3 |
40:1 | ADCC by 17-1A (colo205) or by herceptin (SkBr3) Effector molecule: TNF-α |
[17] |
| CD16+ slan DCs M-DC8+ |
IFN-γ | Capan 1 (pancreatic cancer) MCF-7 Colo205 HT-29 (colon cancer) |
40:1 | ND | [16] |
| CD16+ slan DCs (CHC) | IMQ or resiquimod | Capan-1 HT-29 |
40:1 | ND | [77] |
| MoDCs | |||||
| MoDCs (measles) |
Measles | T cells (autologous) | 1:1 | TNF family member (postulated) | [19] |
| MoDCs | LPS | Jurkat Molt (T cell leukemia) K562 THP-1 (monocytic cancer) U937 (lymphoma) |
1:1 | Contact dependent | [78] |
| MoDCs | Measles virus | MDA231 | 50:1 | TRAIL | [18] |
| MoDCs | Immature | OVA.1 (ovarian cancer) SW626 (ovarian cancer) |
40:1 | FAS-L | [31] |
| MoDCs | Immature | SiHA, Caski (HPV+ cervical cancer) | 8:1 | Contact-dependent no involvement of TRAIL or FAS-L |
[79] |
| MoDCs CD14+, CD34+ |
IFNβ | HL60 (leukemia) | 20:1 | TRAILa | [25] |
| MoDCs | dsRNA → CD40L → |
MDA231 MDA231 |
50:1 50:1 |
TRAILa TNF-α |
[24] |
| MoDCs | CMV | CMV-reactive T cells | 1:53 | FAS-L, TRAIL | [20] |
| MoDCs | Immature | Jurkat Molt MCF-7 (breast cancer) U87 (glioblastoma) HCT-5 (colorectal cancer) A498 (renal cancer) 786.O (renal cancer) Caki.2 (renal cancer) |
10:1 | Caspase 8 (FADD independent) | [33] |
| MoDCs | CD40L | PCI-13 SSCHN (head and neck cancer) |
1:1 | TNF-α, LT-α, LT-β, FAS-L, TRAILa | [29] |
| MoDCs | CD40L, LPS | MCF-7 MDA-MB-468 (breast cancer) SK-BR-3 (breast cancer) |
? | TNF-αa Contact independent |
[30] |
| MoDCs | HIV-1 IFNα |
MDA231 CD4+ T cell line HIV-H9 CD4+ T cells (HIV-1 viremic patients) |
? | TRAILa, FAS-La, TNF-αa TWEAKa |
[21] |
| MoDCs | HIV-1 (nef) | CD8+ T cells | ? | sTNF-α FAS-L |
[22] |
| MoDCs | Immature | Jurkat | 10:1 | Caspase 8/Bcl-2 (FADD independent) | [35] |
| Cordblood MoDCs |
IFNγ → LPS → |
HL60, Jurkat Daudi, Jurkat |
20:1 | ND | [80] |
| MoDCs | IFNα | K562 | 20:1 | ND | [81] |
| MoDCs | HIV-1 (Vpr) + LPS | Allogeneic CD8+ T cells | 1:20 | sTNF-α | [23] |
| MoDCs | U251 (glioma) Jurkat |
20:1 | Contact dependent FADD and caspase-8 dependent |
[34] | |
| MoDCs | IFNα | K562 | 50:1 | TRAILa | [26] |
| MoDCs | OK432 | T2 K562 EJ 253J |
10:1 | Contact dependent (CD40–CD40L | [82] |
| MoDCs | Immature (CD123+) | U937 Jurkat HL-60 |
40:1 | TRAIL | [83] |
| MoDCs | CD40L | OSC-70 (oral squamous cell carcinoma) |
1:8 | TRAILa IFN-γ |
[28] |
| MoDCs (PB and CB) |
SARS coronavirus | ND | ND | TRAIL | [84] |
| MoDCs | LPS | SkBr3 (Her2-neu+ breast cancer) | 100:1 | ADCC by trastuzumab | [85] |
| MoDCs | LPS | MCF7 (breast) HeLa (cervix) HT29, HCT116, SW480 (colorectal) no killing of T lymphocytes |
5:1 | peroxynitrites | [86] |
| MoDCs (TBC) |
IFNα, LPS | CD4+ T cells CD8+ T cells |
10:1 | PD-L1 | [37] |
| MoDCs | IFNγ, LPS | T47D (breast cancer) | ND | ND | [87] |
| MoDCs | IL-15 | K562 | 50:1 | Granzyme B, TRAILa | [27] |
| MoDCs (CHC patients)b |
LPS | Allogeneic healthy CD4+ T cells Autologous CD4+ T cells |
4:1 | FAS-L, PD-L2, Contact dependent |
[32] |
| MoDCs | γ-irradiated HT-29 | HT-29 (colon cancer) | 20:1 | Perforin/granzyme B | [36] |
a
Partially dependent, other mechanisms (shown when possible) may be involved.
b
Chronic hepatitis C patients.
c
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; CB, cord blood; E: T ratio, effector cell to target cell ratio; FADD, FAS-associated protein with death domain; HPV, human papillomavirus; ND, not determined; PB, peripheral blood; TGF, transforming growth factor.